Results of CytoDyn’s PRO 140 CD01 Trial and Extension Study Published in HIV Clinical Trials May 24, 2018 5:00pm EDT
CytoDyn to Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM Microbe 2018 Apr 11, 2018 4:30pm EDT
CytoDyn Forms Scientific Advisory Board to Advance PRO 140 Development in Immunological Disorders Mar 29, 2018 6:00am EDT
CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection Feb 20, 2018 6:00am EST
Independent Data Monitoring Committee Recommends Continuation of CytoDyn’s PRO 140 Pivotal Combination Therapy Trial as Planned Without Modifications to Achieve Primary Endpoint Dec 07, 2017 6:00am EST
CytoDyn’s PRO 140 Monoclonal Antibody Prevents Graft-Versus-Host Disease in Model of Bone Marrow Stem Cell Transplantation Nov 14, 2017 6:00am EST
CytoDyn Provides Update on PRO 140 Combination Therapy Pivotal Trial in HIV Patients Following Constructive Meeting With FDA Oct 13, 2017 6:00am EDT
CytoDyn Receives Orphan Drug Designation for PRO 140 for Prevention of Graft Versus Host Disease Oct 05, 2017 6:00am EDT
